Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDG-4131
- Development stage
- Preclinical
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EDG-4131 is a selective, orally bioavailable small molecule inhibitor of fast skeletal muscle myosin (specifically fast skeletal myosin II) originally developed by Edgewise Therapeutics and subsequently acquired by Servier in 2026. It is designed to protect skeletal muscle from contraction-induced mechanical stress and injury, and to reduce downstream inflammatory signaling. In preclinical models, EDG-4131 has demonstrated efficacy in improving muscle pathophysiology and molecular pathology in Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD) models, as well as restoring muscle performance in models of nemaline myopathy type 6 (NEM6).
02
Targets
MYH2
Beyond the preview
Go deeper on EDG-4131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDG-4131.